Related Experiment Video

Updated: Jun 5, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

[A systematic review of vasodilators for sudden sensorineural hearing loss]

Meiqun Wang1, Yuehui Liu, Zhaowen Du

  • 1Department of Otolaryngology, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China.

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery
|December 24, 2010
PubMed

Insights

Current evidence does not support using vasodilators for sudden sensorineural hearing loss (SSNHL). More high-quality trials are needed to determine their true efficacy and safety in treating SSNHL.

Area of Science:

  • Otolaryngology
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Sudden sensorineural hearing loss (SSNHL) is an otologic emergency.
  • Vasodilators are sometimes used to treat SSNHL, but their effectiveness is debated.

Purpose of the Study:

  • To systematically review and meta-analyze the efficacy and safety of vasodilators for treating SSNHL.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases.
  • Included randomized controlled trials (RCTs) comparing vasodilators to placebo or other drugs.
  • Meta-analysis was performed on homogeneous study data using RevMan software.

Main Results:

  • Twenty-eight RCTs met the inclusion criteria.
  • Seven studies indicated vasodilators were not more effective than placebo.
  • Comparisons between different vasodilators or vasodilators and other drugs yielded no definitive conclusions.

Conclusions:

  • Existing evidence does not support the use of vasodilators for SSNHL treatment.
  • Further rigorous, randomized, double-blind, placebo-controlled trials are necessary to establish efficacy and safety.
Abstract

More Related Videos

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)

Published on: February 27, 2018

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...